[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophageal-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophageal-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,74,111,144,170,194,226,261,282,309,328,357,380,407],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100580290","comparative-assessment-of-esophagitis-in-cases-with-and-without-esophageal-motility-disorders-a-prospective-study-100580290",false,"NCT06835374","Comparative Assessment of Esophagitis in Cases With and Without Esophageal Motility Disorders: A Prospective Study","Comparative Assessment of Reflux Esophagitis in Cases With and Without Esophageal Motility Disorders","Inclusion Criteria:\n\n1. Age≥18y,\n2. confirmed diagnosis of Achalasia,\n3. No contraindication to POEM,\n4. erosive esophagitis on endoscopy\n\nExclusion Criteria:\n\n1. Non-esophageal esophageal motility disorders,\n2. Treatment other than POEM,\n3. current PPI use before assessment for GERD","ALL","18 Years","75 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","Achalasia is a neuro-degenerative disorder marked by changes in the peristalsis of the esophagus and the lack of relaxation in the lower esophageal sphincter (LES), thought to be due to damage to the myenteric plexus with an unknown cause.1 Per-oral endoscopic myotomy (POEM) is an established endoscopic treatment modality for achalasia. Leading gastrointestinal (GI) societies endorse POEM as one of the primary treatment option for achalasia.This study aims to characterize and compare the morphological characteristics of reflux related erosions after the POEM procedures versus those in cases without esophageal motility disorders.\n\nData collection\n\n1. Demographic characteristics: Age, gender, type of achalasia\n2. Manometry findings (pre and post POEM): integrated relaxation pressure, lower esophageal sphincter pressure\n3. Comorbidities\n4. Medications\n5. Eckardt score: before procedure and 3-months after Procedure\n6. POEM procedure details: length of esophageal and gastric myotomy, adverse events, length of hospital stay\n7. Evaluation at 3-months Symptom: standardized questionnaire (GERDQ) Endoscopy: grade of esophagitis Erosions vs ulcers Dimension of erosions Anatomical location (according to clock)",[27],"Esophageal Diseases","RECRUITING","2026-05-30",{"date":31,"type":32},"2026-06-03","ACTUAL",{"date":34,"type":32},"2024-05-11",{"date":36,"type":21},"2027-05-10",{"name":38,"class":39},"Asian Institute of Gastroenterology, India","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":40},"100637610","prospective-multicenter-screening-for-thoracic-disease-via-radiography-100637610","NCT07585214","Prospective Multicenter Screening for Thoracic Disease Via Radiography","Thoracic Disease Screening Via Radiography: a Prospective Multicenter Study","PROMPT","Inclusion Criteria:\n\n* Age over 18.\n* Ability to understand and willingness to sign a written informed consent form.\n* Individuals presenting for routine health examinations or community-based screening.\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating, or planning to become pregnant during the study period.\n* Physical limitations preventing stable positioning or breath-holding, or presence of metallic implants that may significantly degrade image quality.\n* Known history of advanced thoracic diseases currently under treatment (e.g., active lung cancer, end-stage pulmonary fibrosis, or congestive heart failure).\n* Individuals who have undergone chest CT or X-ray examinations within the past 3 months.",true,{"count":51,"type":21},300000,"5 Years","OBSERVATIONAL","This multicenter, prospective study aims to evaluate the real-world clinical utility of chest X-ray (CXR) for large-scale thoracic disease screening. Adult participants presenting for health examinations will undergo digital CXR screening, and any suspected abnormalities will be confirmed via a gold standard reference, such as a chest CT scan or clinical follow-up. The primary outcome measure is the detection rate (screening yield) of confirmed thoracic conditions. Secondary measures will assess diagnostic accuracy (sensitivity and specificity), false-positive rates, and multi-center reading consistency. By providing prospective, large-cohort evidence, this research seeks to validate the cost-effectiveness and feasibility of CXR in identifying early-stage lung, pleural, and cardiac abnormalities, ultimately guiding public health strategies and optimizing early medical intervention.",[56,57,27],"Pulmonary Diseases","Respiratory Disease",[47,59,60,61,62,63],"Thoracic","Screen","Radiography","Multicenter","Prospective","2026-05-09",{"date":66,"type":32},"2026-05-13",{"date":68,"type":21},"2026-05-01",{"date":70,"type":21},"2029-12-31",{"name":72,"class":73},"Chinese Academy of Sciences","OTHER_GOV",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":85,"studyType":53,"phases":4,"briefSummary":86,"conditions":87,"keywords":99,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":40},"100540310","seattle-spatial-transcriptomic-research-in-inflammatory-bowel-disease-evaluation-stride-100540310","NCT06315179","Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)","Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation","STRIDE","Inclusion Criteria:\n\n* Suspected diagnosis of CD (Crohn's Disease), UC (Ulcerative Colitis) or Indeterminate colitis (IC)\n\nExclusion Criteria:\n\n* Evidence of Other Complicating Medical Issues:\n* Other serious medical conditions, such as neurological, liver, kidney, or systemic disease\n* Pregnancy\n* Tobacco, alcohol, or illicit drug abuse","6 Years","21 Years",{"count":20,"type":21},"3 Years","This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut inflammation.",[88,89,90,91,92,93,27,94,95,96,97,98],"Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis","Indeterminate Colitis","Functional Abdominal Pain Syndrome","Functional Bowel Disorder","Gastroduodenal Disorder","Bowel Dysfunction","Gallbladder Diseases","Sphincter of Oddi Dysfunction","Anorectal Disorder",[100,101],"IBD","DGBI","2026-04-21",{"date":104,"type":32},"2026-04-24",{"date":106,"type":32},"2024-05-10",{"date":108,"type":21},"2030-01",{"name":110,"class":39},"Seattle Children's Hospital",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":40},"100077248","esophageal-cancer-risk-registry-100077248","NCT00260585","Esophageal Cancer Risk Registry","Inclusion Criteria:\n\n* Known or suspected esophageal or gastroesophageal junction malignancy\n* Known Barrett's metaplasia\n* Clinical management of symptomatic gastroesophageal reflux disease (GERD)\n* Achalasia\n* Hiatal hernia\n\nExclusion Criteria:\n\n* Elevated pre-operative bloodwork will not have the additional biopsies taken.\n* Platelet count less than 150,000, partial thromboplastin time (PTT) of 50 or above, and\u002For International Normalized Ratio (INR) of 1.8 or above will not have the additional biopsies taken.",{"count":118,"type":21},7000,"The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identifying genetic and behavioral risk factors involved in the development of esophageal cancer might allow for early detection and prevention. Survival and an opportunity for a cure with esophageal cancer will depend greatly on the stage of diagnosis. Tumors can develop changes in their genetic (hereditary) make-up, and these changes can sometimes be seen in normal tissues before the development of cancer. These genetic (hereditary) changes can serve as tumor markers and can be detected using methods that study changes in genetic material like DNA and RNA. The analysis of proteins can provide additional information. By identifying changes in these molecules that are different or altered in cancer, the investigators can use methods and tests for the detection of these changes.",[121,122,27,123,124],"Esophageal Cancer","Gastroesophageal Reflux Disease (GERD)","Hiatal Hernia","Esophageal Achalasia",[126,127,128,129,130,131,132,133,134],"gastroesophageal reflux disease","GERD","hiatal hernia","achalasia","Barrett's metaplasia","Anti-Reflux Surgery","Known\u002Fsuspected esophageal\u002Fgastroesophageal junction tumor","Esophageal disorders such as Barrett's metaplasia","Symptomatic gastroesophageal reflux disease","2026-04-09",{"date":137,"type":32},"2026-04-14",{"date":139,"type":32},"1999-06",{"date":141,"type":21},"2050-12",{"name":143,"class":39},"University of Pittsburgh",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":153,"studyType":53,"phases":4,"briefSummary":154,"conditions":155,"keywords":159,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":40},"100631904","prospective-registry-of-esophageal-motility-100631904","NCT07506746","PRospective Registry of Esophageal Motility","PREM","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the study.\n2. The procedures are the standard of care for the patient or the participant is taking the medicinal product according to clinical practice\n3. Aged \\> 18 years.\n4. Any typical (heartburn or regurgitation) or atypical reflux symptom (Laryngeal Cough, laryngitis, sub-glottic stenosis, globus, laryngeal cancer, vocal cord granuloma, vocal cord irritation, vocal cord polyps and post-nasal drip; Oropharyngeal: Dental erosion, pharyngitis, sore or burning throat, gingivitis and halitosis; Ears and sinuses: Earaches, otitis media and sinusitis; Pulmonary: Chronic bronchitis, pneumonia, aspiration, bronchiectasis, asthma and idiopathic pulmonary fibrosis; Cardiac: Arrhythmia, angina and myocardial infarction; Sleep: Sleep apnoea, sleep deprivation, insomnia, snoring, nightmare and sleep disturbance), but also any obstructive esophageal symptom potentially reflecting a primary or secondary motility disorder (oropharyngeal or esophageal dysphagia, chest pain, bolus impaction). Every patient with a diagnosis of esophageal inflammatory disorder (including EoE and others) or systemic rheumatological condition (scleroderma, systemic sclerosis, lichen planus and others), every patient previously undergone to any anti-reflux surgery, bariatric surgery, endoscopic or surgical esophageal or gastric myotomy (also for gastroparesis) may be included.\n5. Patients must be referred to the Digestive Physiopathology Unit of IRCCS San Raffaele Hospital for motility tests\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Not willing to provide informed consent to the inclusion in the registry",{"count":152,"type":21},10000,"10 Years","Digestive physiopathology is a branch of gastroenterology aiming to study patients with upper GI symptoms, mainly gastro-esophageal, potentially indicating the presence of Gastroesophageal Reflux Disease (GERD)\u002FBarrett Esophagus (BE) or obstructive esophageal motility disorders (achalasia being the most relevant), but including also other primary motility disorders such as Esophgago-Gastric Junction Outflow Obstruction (EGJOO), Hypercontractile Esophagus (HE), Distal Esophageal Spasm (DES) and other minor disorders. Physiopathological testing encompasses High-Resolution Manometry (HRM), 24-H esophageal pH-impedance testing, Functional Lumen Imaging Probe (FLIP) assessment. All these tests are designed to provide a clear phenotyping of esophago-gastric disorders related to reflux or obstructive esophageal symptoms, either in naïve patients, as well as after foregut surgery (particularly anti-reflux surgery, achalasia\u002Fprimary motility disorders treatment).",[27,156,157,158,127],"Achalasia","Eosinophilic Esophagitis","Motility Disorder",[160],"Esophageal disease; manometry; FLIP, pH-impedance","2026-03-28",{"date":163,"type":32},"2026-04-02",{"date":165,"type":32},"2026-03-09",{"date":167,"type":21},"2041-03",{"name":169,"class":39},"IRCCS San Raffaele",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":40},"100386507","clinical-utility-of-wats3d-a-5-year-prospective-study-100386507","NCT04312633","Clinical Utility of WATS3D: A 5-Year Prospective Study","CDx Study 906: The Clinical Utility of WATS3D (Wide Area Transepithelial Sampling With Computer-Assisted 3-Dimensional Analysis): A 5- Year Prospective Registry","Inclusion Criteria:\n\n* Able to read, comprehend and complete the IRB-approved consent form\n* Aged 18 or older\n* Meet one of the following:\n* Patients with heartburn or regurgitation undergoing a screening EGD, who undergo WATS3D sampling and forceps biopsies for suspicion of BE, or\n* Patients with known BE with or without dysplasia undergoing a surveillance EGD with WATS3D biopsies and forceps biopsies, or\n* Patients who have undergone endoscopic eradication (i.e. radiofrequency ablation or cryoablation) who are undergoing surveillance EGD following the establishment of complete eradication of intestinal metaplasia (CEIM)\n* Only patients who undergo both forceps biopsies and WATS3D of the esophagus will be included.\n\nExclusion Criteria:\n\n* Pregnancy at time of endoscopy\n* Unresolved drug or alcohol dependency that will limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions or follow-up guidelines\n* Medical condition that will likely prohibit completion of a 5 year study",{"count":178,"type":21},90000,"The purpose of this study is to create a registry (collect data and keep it in a research database) to learn more about two methods of taking small tissue samples from your esophagus (the esophagus is the tube that carries food and liquid from your mouth to your stomach). The two methods of sampling are: 1) Using forceps that take biopsies (small tissue samples) from your esophagus, and 2) Using a brush that also takes biopsies from your esophagus.",[181,182,183,27],"Barrett Esophagus","Gastro Esophageal Reflux","Esophageal Dysplasia","2026-03-18",{"date":186,"type":32},"2026-03-20",{"date":188,"type":32},"2020-04-01",{"date":190,"type":21},"2027-11-01",{"name":192,"class":193},"CDx Diagnostics","INDUSTRY",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100506662","phase-1-safety-and-feasibility-study-of-the-cellspan-esophageal-implant-cei-in-patients-requiring-short-segment-esophageal-replacement-100506662","NCT05877300","Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement","Inclusion Criteria Cohort 1:\n\n1. Subject ≥18 years of age\n2. The patient has medical conditions requiring esophageal reconstruction, such as, but not limited to:\n\n   1. Refractory benign esophageal strictures (RBES)\n   2. Esophageal perforation (full thickness)\n   3. Chronic\u002Fpersistent esophageal fistula\n   4. Combination of esophageal perforations\u002Ffistula with RBES\n3. The patient must have failed at least 3 previous treatment modalities to correct the medical esophageal condition (a-d).\n\n   a. If RBES: i. Steroid treatment ii. Esophageal balloon dilation (EBD) iii. Stent use ≥ 6 months iv. Endoscopic incisional repair\n\n   b. If esophageal perforation: i. Fibrin glue ii. Endoscopic clips and\u002For suturing iii. Stent use ≥ 6 months iv. Primary surgical repair\n\n   c. If Chronic\u002FPersistent fistula(e): i. Fibrin glue ii. Endoscopic clips and\u002For suturing iii. Stent ≥ 6 months iv. Primary surgical repair\n\n   d. If Combination Perforation\u002Ffistula with RBES i. Fibrin glue ii. Endoscopic clips and\u002For suturing iii. Stent use ≥ 6 months iv. Primary surgical repair\n4. The patient must be a surgical candidate for a short segment esophageal reconstruction (≤6 cm full circumferential segmental excision)\n5. The location of the esophageal segment for surgical resection is within the thoracic cavity, defined as, above the diaphragm and at least 4 cm below the larynx.\n6. The patient must be a high-risk candidate for minimally invasive esophageal reconstruction, based upon the investigator's determination. The patient requires a thoracotomy to repair the esophagus and is not amenable for laparoscopic or robotic minimally invasive gastric pull-up (GPU) surgery, due to a medical contraindication\n7. All patients must be made aware and must be amenable to a delayed rescue repair surgical procedure in the event the CEI fails to restore a patent durable biologic esophageal conduit\n8. The patient\u002Fguardian is willing and able to comply with the protocol specified medication regimen and follow-up evaluations\n9. The patient\u002Fguardian has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC)\n\nInclusion Criteria Cohort 2:\n\n1. Subject ≥18 years of age\n2. The patient has medical conditions requiring esophageal reconstruction, limited to:\n\n   a. Spit Fistula with an upper esophageal ostomy in the neck\n3. Patients may require esophageal de-functioning with a resulting cervical spit fistula if they are not candidates for immediate esophageal reconstruction. This may occur for multiple reasons, including being too sick for reconstruction, healing of the airway after tracheo-esophageal fistula repair, requirement for further therapy prior to reconstruction, or recovering from sepsis due to esophageal perforation.\n4. The patient must be a surgical candidate for a short segment esophageal reconstruction (\\\u003C 7cm), a full circumferential segmental esophageal extension in order to have sufficient length to make the anastomosis to the distal thoracic esophagus, to a gastric or to an intestinal interposition conduit that will re-establish oral nutritional intake. i.\n5. Patient must be a high-risk candidate for the standard of care treatment of esophageal reconstruction, based upon the investigator's determination. The patient requires a thoracotomy to repair the esophagus following the CEI subdermal extension procedure and is not amenable for laparoscopic or robotic minimally invasive gastric pull-up (GPU) surgery.\n6. All patients must be made aware and must be amenable to a delayed rescue repair surgical procedure in the event the CEI fails to mature in the subdermal area prior to mobilization\n7. The patient\u002Fguardian is willing and able to comply with the protocol- specified medication regimen and follow-up evaluations\n8. The patient\u002Fguardian has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).\n\nExclusion Criteria all cohorts:\n\n1. Subject requires or undergoes an esophageal segmental excision \\>6 cm in length\n2. Esophageal segment extends below the diaphragm or \\\u003C4 cm below larynx\n3. Pre-existing implants\u002Fstructures adjacent to target surgical location for implant that could cause abrasion of the scaffold\u002Fregenerated tissue (e.g., pacemaker lead, vascular clips, vascular grafts).\n4. Known clinical contraindication that would obfuscate the use of the covered metallic stent to be used as an adjunct to the procedure\n5. Post ablation stricture for Barrett's esophagus treated less than 1 year prior to planned procedure\n6. Patient has a comorbidity or contraindication that would preclude any study required procedures including adipose tissue biopsy and esophageal resection surgery. Comorbidities are defined from a subset of the Charlson Comorbidities Index (CCI, Yamashita 2018) scoring system and include:\n\n   1. diabetes mellitus (CCI = 1)\n   2. connective tissue disorders (CCI=1)\n   3. immune compromised\n   4. chemotherapy radiotherapy or chemoradiotherapy (within 60 day clearance)\n   5. inability to tolerate major thoracotomy\n   6. active infection at the biopsy or thoracotomy incision site\n   7. peripheral vascular disease (CCI=1)\n   8. all patients with a CCI\\> 2\n7. Life expectancy of less than 1 year\n8. Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following the index procedure. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7days prior to index procedure.\n9. Has a known untreated neurological, psychological, psychiatric, or other disorder that would interfere with trial endpoints or with cooperation with the requirements of the trial\n10. Has a diagnosis of immunodeficiency, receiving cancer therapy including chimeric antigen receptor T cells (CAR-T), receiving systemic steroid therapy (\\>10 mg prednisone or equivalent daily dose), or any other form of pharmacologic therapy that would inhibit the intended cell growth (e.g., protease inhibitors, immunosuppressants, anti-cytokine therapies) within 30 days prior to index procedure or intended for use during any time after implantation through 12 months post-index procedure.\n11. Patient with an infection requiring antibiotic therapy\n12. Known allergy to Nitinol (for adjunctive self-expanding covered metallic stent procedure)\n13. Current participation in another investigational drug or device study\n14. Patient is a prisoner\n15. If in the opinion of the investigator, the patient requires pain management (potentially opioid medications) as a result of study participation, the patient is at an unreasonable risk of addiction. This decision may be based upon medical or social history, personal situation, or the expected time course, length, and type of medication use.",{"count":201,"type":21},10,[203],"PHASE1","Cellspan™ Esophageal Implant-Adult (CEI)\n\nThe CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stem cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.\n\nThis is a dual arm, unblinded, multicenter, prospective first-in-human (FIH) feasibility study to be performed at a maximum of 5 centers in the United States with a maximum of 10 subjects in total. All subjects will be followed for a minimum of 2 years post-implant surgery.\n\nSince this is an FIH experience, the study will utilize an independent Data Monitoring Committee (DMC) to evaluate safety on a continuous basis to mitigate any safety risks to subjects. A sentinel approach to enrollment of subjects shall be guided by the DMC review of cases.",[27],[207,208,209,210,211,212,213,214,62,215,216],"Esophagus","Esophagectomy","Tissue Engineering","Organ Regeneration","Regenerative Medicine","Cell Therapy","Dual Arm","Unblinded","FIH","CEI",{"date":218,"type":32},"2026-03-11",{"date":220,"type":32},"2023-07-13",{"date":222,"type":21},"2026-12",{"name":224,"class":193},"Harvard Apparatus Regenerative Technology, Inc.",3,{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":232,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":239,"conditions":240,"keywords":245,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":40},"100571535","phase-2-effectiveness-of-methods-for-pyloric-drainage-in-esophagectomy-botox-vs-pyloromyotomy-100571535","NCT06721520","Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy","Comparative Effectiveness of Intrapyloric Botulinum Toxin Injection Versus Pyloromyotomy for Pyloric Drainage During Esophagectomy: A Registry-Based, Pragmatic Randomized Noninferiority Trial","EMPTY","Inclusion Criteria:\n\n* 18 years of age or older\n* Undergoing elective esophagectomy (thoracoabdominal, Ivor-Lewis, McKeown)\n* Receiving a gastric conduit for alimentary reconstruction\n* Technically able to receive either intrapyloric Botox injection or pyloromyotomy as ultimately determined intraoperatively\n* Willing and able to provide informed consent\n* Willing and able to participate in long-term follow up including study visits and surveys\n\nExclusion Criteria:\n\n* Undergoing emergent esophagectomy (e.g., for esophageal perforation)\n* Patients with underlying neuromuscular disease as Botox would be contraindicated (amyotrophic lateral sclerosis, myasthenia gravis, muscular dystrophies, Lambert-Eaton syndrome)\n* Patients undergoing left thoracoabdominal without left cervical neck incision (i.e., Sweet esophagectomy) - excluded due to the extent of gastric resection\n* Pregnancy\n* Allergy or hypersensitivity to botulinum toxin\n* Cannot feasibly receive both pyloric interventions as determined intraoperatively (e.g., patients with central obesity undergoing thoracoabdominal esophagectomy makes for a technically difficult pyloromyotomy)",{"count":235,"type":21},170,[237,238],"PHASE2","PHASE3","The goal of this pragmatic, registry-based, randomized clinical trial is to find out if using botulinum toxin (Botox) to help drain the stomach during an esophagectomy works as well as a pyloromyotomy in patients undergoing elective esophagectomy for benign or malignant esophageal disease. Both methods are intended to prevent problems with food emptying too slowly from the stomach (delayed gastric emptying), which can cause discomfort after surgery. The main question it aims to answer is:\n\nIs intrapyloric Botox injection as a drainage procedure during esophagectomy non-inferior in preventing symptoms of delayed gastric emptying at 6 months postoperatively compared to pyloromyotomy?\n\nResearchers will compare intrapyloric Botox injection to pyloromyotomy to see if Botox is non-inferior to pyloromyotomy in easing symptoms of delayed gastric emptying.\n\nParticipants will:\n\nBe randomized to one of two treatment groups-either intrapyloric Botox injection or pyloromyotomy-during their esophagectomy.\n\nComplete surveys assessing digestive symptoms at standard postoperative follow-up intervals (3 months, 6 months, 1 year, and 2 years postoperatively).\n\nUndergo a standard gastric emptying study at 6 months after surgery.",[241,208,242,27,124,243,244],"Esophageal Cancer Surgery","Delayed Gastric Emptying Following Procedure","Pylorus Dysfunction","Esophageal Dysmotility",[208,246,247,248,249,250,251],"Delayed gastric emptying","Delayed conduit emptying","Botox","botulinum toxin","Pyloromyotomy","Pyloric drainage","2026-02-23",{"date":254,"type":32},"2026-02-25",{"date":256,"type":32},"2024-12-03",{"date":258,"type":21},"2028-05-31",{"name":260,"class":39},"The Cleveland Clinic",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":268,"maxAge":18,"enrollmentInfo":269,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":274,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":279,"leadSponsor":281,"locationsCount":4},"100617934","comparison-of-conventional-and-short-submucosal-tunnel-techniques-in-type-ii-achalasia-100617934","NCT07325071","Comparison of Conventional and Short Submucosal Tunnel Techniques in Type II Achalasia","A Randomized Controlled Trial Comparing Conventional and Short Submucosal Tunnel Techniques in Type II Achalasia","Inclusion Criteria:\n\n1. Adults aged \\>18 years.\n2. Diagnosis of Type II achalasia naïve patients based on high-resolution manometry (Chicago Classification v4).\n3. Eckardt score \\>3.\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Type I or III achalasia.\n2. Previous endoscopic or surgical treatment for achalasia.\n3. Contraindications for POEM (e.g., coagulopathy, portal hypertension).\n4. Sigmoid Achalasia","19 Years",{"count":270,"type":21},636,[24],"Rationale for This Study The primary rationale for this study is to evaluate whether a shorter submucosal tunnel during POEM with an EGJ-focused myotomy in type II Achalasia cardia patients, provides equivalent or superior symptom relief compared to the conventional approach while minimizing adverse events such as GERD \\& blown out myotomy and decreasing the procedure time.\n\nObjectives\n\nPrimary Objective:\n\nTo compare the incidence of GERD (with manual review) at 3 and 12 months' post-procedure between conventional POEM and two experimental short-tunnel POEM techniques in patients with Type II achalasia.\n\nSecondary Objectives:\n\nTo evaluate\n\n1. Clinical success based on Eckardt score\n2. Operating total procedure time\n3. Use of Acid Suppressants on Follow up at 1 year\n4. Severity of Esophagitis at 3 months\n5. Intraoperative \\& Postoperative adverse events (AGREE classification),\n6. GERD-HRQL (0-18) scores 3 \\& 12 Months\n7. (Clinically relevant GORD was defined as excessive oesophageal \u002FAET associated with a GERDQ score \\>7 and\u002For with any grade of reflux oesophagitis).\n8. Duration of Hospital stay\n9. Quality of life (SF36)",[27],"NOT_YET_RECRUITING","2025-12-31",{"date":277,"type":32},"2026-01-08",{"date":275,"type":21},{"date":280,"type":21},"2027-07-30",{"name":38,"class":39},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":40},"100367760","esophageal-and-gastric-diseases-with-robotically-controlled-magnetic-capsule-endoscopy-100367760","NCT04068480","Esophageal and Gastric Diseases With Robotically Controlled Magnetic Capsule Endoscopy","Study of Esophageal and Gastric Diseases With Robotically Controlled Magnetic Capsule Endoscopy","MACEOES","Inclusion Criteria:\n\n\\- patients referred for small bowel capsule endoscopy in any indication\n\nExclusion Criteria:\n\n* known or suspected stricture in the GI tract\n* previous surgery with bowel anastomosis\n* swallowing complaints\n* dementia\n* implanted cardioverter defibrillator\n* inability to sign the informed consent",{"count":291,"type":21},300,"Magnetically controlled capsule endoscopy (MCCE) is an outstanding opportunity for the painless endoscopic screening of the esophagus and stomach before small bowel examiantion. Further improvement in patients positioning might increase the esophageal transit time of the capsule endoscope and could improve the sensitivity and specificity of the esophageal MCCE investigation. Our present study aimed to compare the visualization of the esophagus (especially the Z-line) with different capsule swallowing protocols.",[294,27],"Video Capsule Endoscopy",[296,297,298,207,299],"capsule endoscopy","magnetically assisted capsule endoscopy","MCCE","non-invasive endoscopy","2025-09-30",{"date":302,"type":32},"2025-10-03",{"date":304,"type":32},"2017-11-15",{"date":306,"type":21},"2027-12-31",{"name":308,"class":39},"Bács-Kiskun County Teaching Hospital",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":315,"targetDuration":4,"studyType":22,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":40},"100583000","standard-versus-oesophago-gastric-junction-complex-myotomy-for-treatment-nave-type-2-achalasia-patients-100583000","NCT06870630","Standard Versus Oesophago-gastric Junction Complex Myotomy for Treatment naïve Type 2 Achalasia Patients","Inclusion Criteria:\n\n* Adult \\>18 years\n* Diagnosis of Type 2 Achalasia cardia based on High resolution manometry.\n\nExclusion Criteria:\n\n* Patients with Type 1 \\& 3 ACHALASIA CARDIA\n* Patients with previous endoscopic or surgical treatment for achalasia\n* Patients with standard exclusion criteria for POEM procedure such as contraindication to general anesthesia, coagulopathy (international normalized ratio \\> 1.5, platelet count \\\u003C 50 000\u002FμL), portal hypertension, pregnancy, breast feeding women, and diffuse scarring in the esophagus due to previous surgery or radiation.",{"count":316,"type":21},158,[24],"\\- Consecutive eligible patients will be randomized in a 1:1 ratio to esophagogastric complex only myotomy or standard myotomy groups. Randomization is done according to the computer-generated algorithm. A clinical research coordinator will prepare the sealed randomization envelops and will hand over to the operating endoscopists before the beginning of the procedure. Written informed consent will be obtained from all participants. In this study, the participants and the care-provider assessing the clinical response to the POEM procedure at 3months will be blinded to the allocation.",[27],"2025-06-09",{"date":322,"type":32},"2025-06-10",{"date":324,"type":32},"2023-11-29",{"date":326,"type":21},"2025-07-30",{"name":38,"class":39},{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":335,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":22,"phases":339,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":40},"100555591","role-of-topical-steroid-injection-with-refractory-benign-esophageal-stricture-endoscopic-dilatation-in-children-100555591","NCT06514079","Role of Topical Steroid Injection With Refractory Benign Esophageal Stricture Endoscopic Dilatation in Children","ISIs","Inclusion Criteria:\n\n* Pediatric patients aged less than 14 years\n* with refractory benign esophageal strictures\n* received a dilatation therapy without triamcinolone injections\n\nExclusion Criteria:\n\n* failure to pass a guide wire secondary to pharyngeal stenosis\n* tracheo-esophageal fistula\n* those who received triamcinolone injections at early dilatation","2 Years","14 Years",{"count":338,"type":21},21,[24],"This clinical trial study included 21 children with refractory benign esophageal strictures. Upper GI endoscopy performed up to the area of stricture, esophageal dilatation done, endoscopy repeated, and steroid injected intralesional under direct endoscopic vision. The effect of the procedure was followed over a period of 12 months by evaluation of number of dilatation, maximum dilator size, periodic dilatation index (PDI) and dysphagia score.",[342,27,343],"Pediatric Disorder","Esophageal Stricture",[345,346,347],"Esophageal stricture","Steroid injection","Esophageal dilatation","2024-07-22",{"date":350,"type":32},"2024-07-23",{"date":352,"type":32},"2022-03-02",{"date":354,"type":21},"2024-08-20",{"name":356,"class":39},"Mohammad Daboos",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":11,"sex":16,"minAge":363,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":274,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":4},"100534827","implementing-enhanced-recovery-after-surgery-eras-protocol-in-patients-undergoing-minimal-invasive-esophagectomy-100534827","NCT06243887","Implementing Enhanced Recovery After Surgery (ERAS) Protocol in Patients Undergoing Minimal Invasive Esophagectomy","Inclusion Criteria:\n\n* 1\\) first detected and endoscopically confirmed esophageal cancer; 2)preoperative evaluation showed no distant metastases and suitable for MIE; 3preoperative clinical stage of I to III\n\nExclusion Criteria:\n\n* 1\\) patients had a history of thoracic or abdominal surgery; 2)patients were IV to VI in the American Society of Anesthesiologists (ASA) physical status classification system; 3)patients had other malignancies; 4)patients had missing clinical data","15 Years","80 Years",{"count":366,"type":21},30,[24],"Detect impact of enhanced recovery after surgery (ERAS) on the outcomes of oesophageal surgery .",[27,370],"Esophagostomy Complication","2024-03-20",{"date":373,"type":32},"2024-03-22",{"date":375,"type":21},"2024-04-01",{"date":377,"type":21},"2027-12",{"name":379,"class":39},"Assiut University",{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":394,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":40},"100487209","phase-2-camrelizumab-combined-with-chemoradiotherapy-in-advanced-esophageal-cancer-100487209","NCT05624099","Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.","Prospective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous Carcinoma","Inclusion Criteria:\n\n1. Sign written informed consent and voluntarily participate in this study;\n2. Patients with esophageal squamous cell carcinoma confirmed by histopathology and\u002For immunohistochemistry (8th edition 2017) had UICC\u002FAJCC TNM stage IVA or oligometastatic stage IVB;\n3. Survival is expected to exceed 3 months\n4. Age 18-75;\n5. ECOG PS 0-2\n6. Never received any systemic anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, targeted and immunotherapy;\n7. Have at least one measurable lesion\n8. Normal function of major organs, including:\n\n   1. Routine blood test (no blood components, cell growth factors, whitening drugs, platelet raising drugs, and anemia correcting drugs are allowed within 14 days before the first use of study drugs)\n\n      White blood cell count ≥ 3.0×10\\^9\u002FL\n\n      Neutrophil count ≥ 1.0×10\\^9\u002FL\n\n      Platelet count ≥ 80×109\u002FL\n\n      Hemoglobin ≥ 80 g\u002FL\n   2. Blood biochemical examination:\n\n   Total bilirubin ≤ 1.5×ULN\n\n   ALT ≤2.5×ULN, AST ≤2.5×ULN,\n\n   Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 45mL\u002Fmin\n9. Subjects have good compliance and cooperate with follow-up\n\nExclusion Criteria:\n\n1. The presence of uncontrollable pleural effusion, pericardial effusion or ascites that require repeated drainage;\n2. Poor nutritional status, BMI \\\u003C 18.5 Kg\u002Fm\\^2; If symptomatic nutritional support was corrected before randomization, enrollment could be considered after evaluation by the principal investigator;\n3. Gastrointestinal bleeding (bleeding volume \\> 200ml\u002F day);\n4. Patients with deep ulcers as determined by the investigator;\n5. Previous allergy to monoclonal antibodies, any component of camrelizumab, paclitaxel, cisplatin or other platinum-based drugs;\n6. Has received or is receiving any of the following medical treatment:\n\n   1. any radiation, chemotherapy or other antitumor drugs for the tumor;\n   2. Being treated with immunosuppressive agents or systemic hormones for immunosuppression purposes (dose \\>10mg\u002F day prednisone or equivalent) within 2 weeks prior to the first use of the study drug; In the absence of active autoimmune disease, inhaled or topical steroids and adrenocorticosteroid replacement at a dose of \\>10mg\u002F day or its equivalent are permitted;\n   3. Received live attenuated vaccine within 4 weeks before the first administration of the study drug;\n   4. Major surgery or severe trauma within 4 weeks before the first use of the study drug;\n7. A history of any active autoimmune disease or autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (which may be considered for inclusion after hormone replacement therapy); Patients with complete remission of psoriasis or childhood asthma\u002Fallergies who did not require any intervention as adults were considered for inclusion, but patients requiring medical intervention with bronchodilators were not included;\n8. A history of immunodeficiency, including being HIV positive, or suffering from another acquired or congenital immunodeficiency disease, or a history of organ transplantation or allogeneic bone marrow transplantation;\n9. The presence of poorly controlled cardiac clinical symptoms or diseases, including but not limited to:\n\n   Such as (1) NYHAII grade or above heart failure; (2) unstable angina pectoris; (3) myocardial infarction occurred within 1 year; (4) Clinically significant supraventricular or ventricular arrhythmias are not well controlled without clinical intervention or after clinical intervention;\n10. Severe infection (CTCAE \\> 2) occurred within 4 weeks before the first use of the study drug, such as severe pneumonia, bacteremia, infection complications requiring hospitalization; Baseline chest imaging examination indicated active pulmonary inflammation, signs and symptoms of infection within 14 days before the first use of study drugs, or the need for oral or intravenous antibiotic treatment, except for prophylactic antibiotic use;\n11. Patients with active pulmonary tuberculosis infection found by medical history or CT examination, or with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or with a history of active pulmonary tuberculosis infection more than 1 year ago but without regular treatment;\n12. The presence of active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 104 copies\u002FmL) and hepatitis C (HCV antibody positive and HCV RNA above the assay limit);\n13. In the judgment of the investigator, there are other factors that may lead to the forced termination of the study, such as the presence of other serious medical conditions (including mental illness) requiring concomitant treatment, alcoholism, substance abuse, family or social factors, and factors that may affect the safety or compliance of the subjects.",{"count":388,"type":21},75,[237],"This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.",[392,27,393],"Esophageal Neoplasms","Digestive System Neoplasms",[395,396,397,398],"Immunotherapy","Platinum","radiotherapy","Paclitaxel","2023-10-17",{"date":401,"type":32},"2023-10-19",{"date":403,"type":32},"2023-08-01",{"date":306,"type":21},{"name":406,"class":73},"Fujian Cancer Hospital",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":40},"100458627","phase-2-anlotinib-hydrochloride-capsules-combined-with-tqb2450-injection-in-esophageal-squamous-cell-carcinoma-patients-100458627","NCT05252078","Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients","An Open, Single Arm, Multicenter, Exploratory Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients as Postoperative Adjuvant Therapy","ALTER-E005","Inclusion Criteria:\n\n* Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.\n* ≥ 18 years old.\n* ECOG performance status of 0-1\n* Patients with esophageal squamous cell carcinoma pathologically diagnosed as T1-2N1-3M0 or T3-4NanyM0.\n* Patients received radical (R0) resection of squamous cell carcinoma with no recurrence in imaging examination within 6-12 weeks after surgery, and need adjuvant therapy assessed by the researchers.\n* Laboratory tests must be met:\n* Neutrophils count =\u002F\\> 1.5 x 109\u002FL, platelets count =\u002F\\> 75 x 109\u002FL, Hb =\u002F\\> 90 g\u002FL, WBC =\u002F\\> 3 x 109\u002FL.\n* total bilirubin =\u002F\\\u003C 1.5 x ULN, ALT and AST =\u002F\\\u003C 2.5 x ULN.\n* Creatinine =\u002F\\\u003C 1.5 x ULN.\n* APTT, INR, PT =\u002F\\\u003C 1.5 x ULN.\n* TSH =\u002F\\\u003C ULN.\n* Myocardial enzymes in the normal range.\n* LVEF =\u002F\\> 50%.\n\nExclusion Criteria:\n\n* Patients received other antitumor adjuvant therapy after surgical resection.\n* Concurrent malignancy (except cured basal cell carcinoma of the skin).\n* Patients was diagnosed cervical esophageal carcinoma.\n* Patients who have received prior targeted therapy (anti-VEGF\u002FVEGFR) or immunity therapy (anti-PD-1\u002FPD-L1\u002FCTLA-4).\n* Patients who are allergic to other monoclonal antibodies.\n* Patients with a history of immunodeficiency (or active autoimmue disease), or other acquired congenital immunodeficiency diseases.\n* Immunosuppressant, systemic, or absorbable local hormone therapy (\\> 10mg\u002F day of prednisone or other equivalent hormone) is required for immunosuppression and continued within 2 weeks of initial administration.\n* Patients with multiple factors affecting oral administration.\n* Uncontrolled pleural effusion, pericardial effusion or ascites that requires repeated drainage.\n* With bleeding tendency. Patients with any bleeding or bleeding event CTC AE grade 3 in the 4 weeks prior to initial administration. The presence of digestive diseases or active bleeding of unresected tumors, or other conditions that the investigator determined which could lead to gastrointestinal bleeding or perforation.\n* Active or untreated CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments.\n* Patients with hypertension who could not be well controlled by antihypertensive drugs (systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg).\n* Patients with myocardial infarction, myocardial ischemia, arrhythmias with poor control (including QTC interval male \\> 450 ms, female\\> 470 ms) and cardiac insufficiency of grade II according to NYHA standard.\n* Active or uncontrolled severe infection (≥ CTC AE Grade 2 infection).\n* HIV test positive.\n* Proteinuria =\u002F\\>2+ and confirmed 24-hour urinary protein quantification \\> 1.0 g.\n* Vaccination with prophylactic or attenuated vaccine within 4 weeks prior to initial administration.\n* According to the investigators' judgment, there are factors that endanger patient or prevent patients from completing the study.",{"count":366,"type":21},[237],"This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy. In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with TQB2450 Injection in treatment of patients with ESCC. The primary endpoint is disease free survival (DFS).",[419,392,27,420,421,393,422,423,424,425,426],"Esophageal Squamous Cell Carcinoma","Gastrointestinal Neoplasms","Gastrointestinal Diseases","Digestive System Diseases","Neoplasms by Site","Neoplasms by Histologic Type","Neoplasms, Squamous Cell","Carcinoma, Squamous Cell","2022-12-14",{"date":429,"type":32},"2022-12-16",{"date":431,"type":32},"2022-06-02",{"date":433,"type":21},"2026-11",{"name":435,"class":39},"Jiangxi Provincial Cancer Hospital"]